CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 No DAC Growth Hormone Pulse Guide 2026

Real Peptides Research TeamEditorial

Updated April 27, 20269 min read

52 WORDS

Short answer

Key takeaways

CJC-1295 without DAC produces growth hormone pulses lasting 90–120 minutes with peak response at 20–40 minutes post-injection, mimicking natural GHRH episodic activity.
The peptide has a plasma half-life under 30 minutes because it lacks the albumin-binding DAC modification, requiring daily or multiple-daily dosing for sustained protocols.
Standard research doses range from 100–200 mcg per injection, reconstituted to 1 mg/mL concentration using bacteriostatic water and stored refrigerated at 2–8°C for up to 28 days.
Temperature excursions above 8°C cause irreversible peptide aggregation. Lyophilised powder must be frozen at −20°C before reconstitution, and reconstituted solution must remain refrigerated.
CJC-1295 no DAC preserves pulsatile GH secretion patterns, avoiding the sustained receptor occupancy and negative feedback associated with DAC-modified or exogenous growth hormone protocols.

Research published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 without DAC (Drug Affinity Complex) generates pulsatile growth hormone release patterns nearly identical to endogenous GHRH. With peak amplitudes reaching 300–500% above baseline within 30 minutes of administration. This isn't the sustained elevation you get from the DAC version. The peptide clears rapidly, mimicking the body's natural secretory bursts rather than creating prolonged supraphysiological levels that trigger negative feedback.

Our team has worked with research protocols using both CJC-1295 variants across hundreds of applications. The difference between them isn't subtle. It's mechanistic. One amplifies your body's existing pulses. The other replaces them.

What is CJC-1295 without DAC and how does it differ from the DAC version?

CJC-1295 without DAC is a synthetic analogue of growth hormone releasing hormone (GHRH) that binds to GHRH receptors on pituitary somatotrophs, triggering episodic growth hormone secretion with a half-life of approximately 30 minutes. Unlike CJC-1295 with DAC. Which extends half-life to 6–8 days through albumin binding. The no-DAC version clears quickly, producing short-duration GH pulses that preserve the body's natural secretory rhythm and avoid sustained receptor desensitisation.

Here's what most overviews miss: CJC-1295 no DAC growth hormone pulse protocols aren't designed to flood receptors continuously. They work by amplifying the amplitude of naturally occurring secretory episodes. The 8–12 pulses your pituitary already generates daily. Without disrupting the ultradian rhythm that protects receptor sensitivity. The DAC modification creates sustained elevation that physiologically resembles exogenous growth hormone administration more than it resembles natural GHRH activity. This article covers the exact mechanisms that differentiate pulsatile from sustained agonism, accurate reconstitution and dosing protocols for research applications, and what preparation mistakes invalidate results entirely.

CJC-1295 No DAC Mechanism: GHRH Receptor Activation Without Albumin Binding

CJC-1295 without DAC functions as a direct GHRH receptor agonist at the anterior pituitary. When administered subcutaneously, the peptide enters systemic circulation and crosses into the hypothalamic-pituitary portal system, where it binds to GHRH receptors (GHRHR) on somatotroph cells. The specialised anterior pituitary cells responsible for growth hormone synthesis and secretion. Receptor activation triggers adenylyl cyclase, elevating intracellular cAMP and mobilising calcium stores, which initiates vesicular exocytosis of pre-synthesised GH granules into circulation.

The critical structural difference: CJC-1295 no DAC lacks the lysine-maleimide modification that allows the DAC version to form covalent bonds with serum albumin. Without albumin binding, plasma half-life remains under 30 minutes. Consistent with endogenous GHRH. Peak GH response occurs 20–40 minutes post-injection, returns to baseline within 90–120 minutes, and generates no detectable peptide presence beyond three hours. This pharmacokinetic profile preserves pulsatility: each dose creates one discrete secretory episode rather than prolonged receptor occupancy.

Research applications using CJC-1295 no DAC typically administer doses of 100–200 mcg per injection, timed to coincide with natural GH pulse windows. Most commonly pre-sleep (aligning with the nocturnal secretory surge) or post-training (exploiting the exercise-induced GH pulse). Multiple daily dosing isn't standard because the peptide doesn't accumulate; each administration is an independent event.

Reconstitution and Storage: Preserving Peptide Integrity

CJC-1295 without DAC is supplied as lyophilised powder requiring reconstitution with bacteriostatic water before use. The lyophilised form must be stored at −20°C before mixing. Once reconstituted, the solution is stable at 2–8°C for up to 28 days. Temperature excursions above 8°C cause irreversible aggregation of the peptide backbone, rendering it biologically inactive without visible degradation.

Reconstitution protocol: Use 2 mL bacteriostatic water per 2 mg vial for a final concentration of 1 mg/mL (1000 mcg/mL). Inject the water slowly down the side of the vial. Never directly onto the lyophilised cake, which can denature surface peptides through mechanical shear. Swirl gently to dissolve; do not shake. The solution should be clear and colourless. Any cloudiness, particulate matter, or discolouration indicates peptide degradation. Discard immediately.

Dosing accuracy depends on syringe precision. A standard 100 mcg dose equals 0.1 mL from a 1 mg/mL solution. Use insulin syringes (U-100, 0.5 mL or 1 mL capacity) with 0.01 mL gradations for accurate measurement. Dosing errors are the most common protocol failure we've seen. Researchers frequently underestimate the importance of syringe resolution when working at microgram scale.

CJC-1295 No DAC vs DAC vs Modified GRF (1-29): Research Application Comparison

Peptide Variant	Half-Life	Dosing Frequency	Peak GH Response Time	Pulse Pattern	Primary Research Use Case	Professional Assessment
CJC-1295 No DAC	~30 minutes	1–3× daily	20–40 minutes	Discrete episodic pulses	Amplifying natural secretory rhythm without sustained elevation	Best for protocols requiring physiological pulsatility. Preserves feedback loops
CJC-1295 with DAC	6–8 days	1–2× weekly	2–4 hours	Sustained elevation with blunted peaks	Creating prolonged GH exposure without frequent dosing	Mimics exogenous GH pharmacokinetics. Higher desensitisation risk
Modified GRF (1-29) (Sermorelin)	~10 minutes	2–4× daily	15–30 minutes	Very sharp, short-duration pulses	Ultra-short pulse amplification with rapid clearance	Most conservative option. Mimics endogenous GHRH most closely
Ipamorelin (GHRP)	~2 hours	1–3× daily	30–60 minutes	Moderate-duration pulses via ghrelin pathway	Synergistic with GHRH analogues. Dual-pathway activation	Often stacked with no-DAC for additive effect without receptor competition

What If: CJC-1295 No DAC Scenarios

What If the Reconstituted Solution Develops Cloudiness After One Week?

Discard it immediately. Cloudiness indicates peptide aggregation or bacterial contamination, both of which render the solution ineffective and potentially unsafe. Aggregated peptides lose biological activity and cannot be recovered by filtration or re-mixing. Bacterial contamination in bacteriostatic water is rare but catastrophic; even if the solution appears clear after cloudiness resolves, structural integrity is already compromised. Reconstitute a fresh vial and verify refrigeration temperature hasn't fluctuated above 8°C.

What If You Miss the Intended Dosing Window During a Pulsatile Protocol?

Administer the dose as soon as you remember if fewer than four hours have passed since the planned injection time, then continue the regular schedule. If more than four hours have elapsed, skip that dose entirely and resume at the next scheduled time. Do not double-dose to compensate. CJC-1295 no DAC works through discrete episodic pulses; the goal is consistent amplification of natural rhythm, not cumulative exposure. Missing one pulse doesn't invalidate the protocol, but disrupting the rhythm with irregular timing reduces the physiological alignment that makes pulsatile administration valuable.

What If You're Combining CJC-1295 No DAC with a GHRP Like Ipamorelin?

Dose them simultaneously or within 15 minutes of each other to exploit synergistic GH release through dual-pathway activation. GHRH receptor agonism (CJC-1295) and ghrelin receptor agonism (ipamorelin) produce additive, not competitive, effects. Typical research combinations use 100–200 mcg CJC-1295 no DAC with 200–300 mcg ipamorelin per pulse. The additive effect can increase peak GH amplitude by 50–100% compared to either peptide alone, based on pharmacological studies in endocrine research models. Keep total pulse frequency to 1–3× daily to avoid receptor desensitisation from chronic stimulation.

The Unvarnished Truth About CJC-1295 No DAC vs DAC Protocols

Here's the honest answer: the 'convenience' of weekly DAC dosing comes with a tradeoff most suppliers don't mention. CJC-1295 with DAC creates sustained receptor occupancy that physiologically resembles exogenous growth hormone administration more than it resembles natural GHRH activity. Your body's pituitary doesn't secrete GH continuously. It pulses 8–12 times per day in response to ultradian rhythm, sleep cycles, and metabolic signals. Those intervals between pulses aren't wasted time; they're when receptors reset sensitivity.

The DAC modification bypasses that rhythm entirely. You get prolonged elevation, but at the cost of blunted peak amplitude over time and increased negative feedback signalling that can suppress endogenous secretion. CJC-1295 no DAC requires more frequent administration, but it works with your physiology instead of overriding it. The pulsatile approach preserves receptor sensitivity, maintains natural feedback loops, and avoids the metabolic adaptation that chronic elevation triggers. If your research goal is amplifying natural GH dynamics rather than replacing them, the no-DAC version is the mechanistically appropriate choice. Even if it's less convenient.

Dosing Precision and Common Protocol Errors

The most frequent mistake researchers make with CJC-1295 no DAC isn't reconstitution technique. It's syringe resolution. A 100 mcg dose from a 1 mg/mL solution requires drawing exactly 0.1 mL. Standard 1 mL insulin syringes have gradations every 0.01 mL (10 units on a U-100 syringe), which allows adequate precision. Using a 3 mL syringe with 0.1 mL gradations. Common in general lab supply kits. Introduces ±50 mcg dosing error, which is unacceptable at this scale.

Another error: injecting air into the vial while drawing solution. The resulting positive pressure pushes liquid back through the needle on subsequent draws, pulling contaminants into the vial and reducing dose accuracy. Correct technique: insert needle with no plunger pressure, invert vial, draw slowly without introducing air. If you need to equalise vial pressure after multiple draws, inject air before inserting the needle fully through the stopper. Not after.

Timing matters as much as dose. CJC-1295 no DAC peaks at 20–40 minutes and clears within two hours. Administering it four hours before a planned activity expecting peak GH response means you've missed the window entirely. Pre-sleep dosing works because the peptide's peak aligns with the body's largest natural nocturnal pulse. Post-training dosing works because exercise creates a brief GH pulse window that the peptide amplifies. Random midday dosing outside these windows produces a measurable pulse but lacks the synergistic amplification that makes pulsatile protocols effective.

Real Peptides produces CJC-1295 no DAC and related research peptides through small-batch synthesis with full amino acid sequencing verification. Every batch includes third-party purity testing via HPLC. Because at microgram dosing scales, even 5% impurity compounds significantly. Our CJC1295 Ipamorelin blend combines both peptides in verified ratios for dual-pathway research applications, and our commitment to batch-level traceability extends across our full catalogue. Including compounds like MK 677 for ghrelin pathway research and Hexarelin for comparative GHRP studies.

The difference between research-grade and commercial-grade peptides shows up in reconstitution clarity, dosing consistency across vials, and stability under refrigeration. If your peptide degrades in ten days instead of twenty-eight, the issue isn't storage. It's synthesis purity. Impurities accelerate aggregation, reduce bioactivity, and introduce variables that invalidate controlled research. There's no recovery protocol for compromised peptides; starting with verified product integrity is the only option.

CJC-1295 no DAC isn't a convenience peptide. It's a precision tool for amplifying physiological GH dynamics without overriding them. And that precision starts before the first injection, at the synthesis and verification stage most researchers never see.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 without DAC produces discrete, episodic GH pulses lasting 90–120 minutes with rapid clearance (half-life under 30 minutes), mimicking natural pulsatile GHRH secretion. CJC-1295 with DAC uses albumin binding to extend half-life to 6–8 days, creating sustained GH elevation rather than discrete pulses — this prolonged receptor occupancy resembles exogenous GH pharmacokinetics and increases risk of receptor desensitisation over time.

Standard research doses range from 100–200 mcg per injection, administered 1–3 times daily depending on protocol goals. Each dose produces one discrete GH pulse with peak response at 20–40 minutes post-injection. Timing is critical — pre-sleep dosing aligns with the nocturnal GH surge, while post-training dosing amplifies the exercise-induced pulse. The peptide does not accumulate; each administration is an independent secretory event.

No — reconstituted CJC-1295 no DAC must be refrigerated at 2–8°C and remains stable for up to 28 days under these conditions. Temperature excursions above 8°C cause irreversible peptide aggregation and loss of biological activity, even if the solution appears visually unchanged. Lyophilised powder must be stored frozen at −20°C before reconstitution. There is no recovery protocol for temperature-compromised peptides.

If fewer than four hours have passed since the planned injection time, administer the dose immediately and continue your regular schedule. If more than four hours have elapsed, skip that dose entirely and resume at the next scheduled time — do not double-dose. CJC-1295 no DAC works through discrete episodic pulses; the goal is rhythm consistency, not cumulative exposure.

CJC-1295 no DAC and Modified GRF (1-29) are structurally nearly identical — both are GHRH analogues without albumin-binding modifications. The primary difference is nomenclature and minor amino acid substitutions that slightly extend Modified GRF’s half-life from endogenous GHRH’s 7 minutes to approximately 10 minutes, compared to CJC-1295 no DAC’s 30 minutes. Functionally, both produce pulsatile GH release; CJC-1295 no DAC generates slightly longer-duration pulses.

Yes — CJC-1295 no DAC (a GHRH analogue) and Ipamorelin (a ghrelin receptor agonist) work through different pathways and produce synergistic GH release when dosed simultaneously. Typical research combinations use 100–200 mcg CJC-1295 with 200–300 mcg Ipamorelin per pulse, generating 50–100% higher peak GH amplitude than either peptide alone. The two peptides do not compete for receptors and can be mixed in the same syringe.

Peak GH response occurs 20–40 minutes post-injection, with measurable elevation beginning within 15 minutes. GH levels return to baseline within 90–120 minutes. The peptide itself clears from circulation within three hours — no detectable plasma concentration remains beyond this window, which is why daily or multiple-daily dosing is required for sustained research protocols.

Discard immediately if the solution develops cloudiness, visible particles, discolouration (yellowing or amber tint), or unusual odour. Properly reconstituted CJC-1295 no DAC is clear and colourless. Cloudiness indicates peptide aggregation or bacterial contamination — both render the solution biologically inactive. Even if cloudiness resolves after refrigeration, structural integrity is already compromised. Peptide aggregation cannot be reversed by filtration or re-mixing.

At research doses of 100–200 mcg, even small volumetric errors create significant dose variation. A 100 mcg dose from a 1 mg/mL solution requires exactly 0.1 mL — using a syringe with 0.1 mL gradations introduces ±50 mcg error (50% dose variance). Insulin syringes with 0.01 mL resolution are required for accurate microgram-scale dosing. Dosing errors compound over multi-week protocols and invalidate dose-response analysis.

CJC-1295 no DAC amplifies natural GH pulses without replacing them, preserving physiological feedback loops when dosed according to pulsatile rhythm. Unlike sustained-release formulations or exogenous GH, episodic GHRH receptor activation allows intervals for receptor resensitisation and does not trigger chronic negative feedback. Prolonged daily use at supraphysiological doses could theoretically suppress endogenous GHRH, but standard pulsatile protocols (1–3 doses daily) maintain natural secretory dynamics.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA